{
  "name" : "dacemirror.sci-hub.se_journal-article_0588349dad431f82c997c12f1db9d802_ma2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Supplemental Table 5. Mediation analysis by fasting serum triglycerides levels for the association of DNA methylation (CpGs) and hepatic fat Triglycerides",
    "authors" : [ ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Supplemental Table 5. Mediation analysis by fasting serum triglycerides levels for the association of DNA methylation (CpGs) and hepatic fat Triglycerides CpG Mediation 95% CI P cg06500161 39% 27% 50% 2.00E-16 cg21429551 15% 6% 27% 2.00E-16 cg19016694 14% 6% 25% 2.00E-16 cg09469355 19% 9% 32% 2.00E-16 cg17901584 29% 17% 50% 2.00E-16 cg14476101 30% 20% 50% 2.00E-16 cg08309687 17% 9% 31% 2.00E-16 cg18120259 23% 12% 42% 2.00E-16 cg05119988 19% 9% 35% 2.00E-16 cg27243685 38% 19% 46% 0.002 cg03957124 13% 5% 24% 0.002 cg11024682 29% 15% 68% 0.002 cg14020176 17% 5% 31% 0.01 cg17501210 13% 2% 29% 0.02 cg19693031 22% 3% 38% 0.03 cg02711608 30% 5% 42% 0.03 cg00574958 47% 11% 93% 0.04 cg26894079 6% -2% 23% 0.09 cg06690548 20% -14% 36% 0.14 cg15860624 7% -3% 20% 0.15 cg11376147 26% -52% 47% 0.17 cg03725309 3% -18% 12% 0.75\nCpG CHR Position Gene Beta SE P N Beta SE P N Beta SE P N\ncg00920337 13 52392151 FLJ37307 -4.6E-03 7.9E-03 5.6E-01 150 -7.4E-04 8.6E-05 5.1E-16 272 1.6E-01 1.9E+00 9.3E-01 297 6.6E-10 2.5E-02\ncg01077808 19 16607011 C19orf44;CALR3 8.4E-03 9.4E-03 3.7E-01 149 4.4E-04 5.9E-05 1.3E-12 272 3.0E+00 2.4E+00 2.1E-01 295 3.5E-09 2.3E-01\ncg15983528 8 1200525 3.3E-03 7.4E-03 6.6E-01 150 -7.1E-04 9.1E-05 1.4E-13 272 -1.2E+00 1.8E+00 4.9E-01 300 4.0E-09 3.9E-01\ncg00395894 19 17881640 FCHO1 -1.5E-02 7.1E-03 4.1E-02 150 -6.6E-04 1.0E-04 2.9E-10 272 -3.9E+00 2.0E+00 4.9E-02 295 6.6E-09 7.2E-01\ncg15534482 14 78324874 ADCK1 -5.1E-03 1.2E-02 6.7E-01 150 -7.1E-04 9.1E-05 1.1E-13 272 3.8E-01 2.7E+00 8.9E-01 292 1.2E-08 6.0E-01\ncg07254987 12 117697516 NOS1 -7.9E-03 6.4E-03 2.2E-01 150 -4.5E-04 6.6E-05 6.3E-11 272 -2.0E+00 1.9E+00 3.1E-01 299 2.8E-08 5.4E-01\ncg04350355 22 36962768 CACNG2 -4.2E-02 5.3E-02 4.2E-01 150 -8.4E-04 1.4E-04 5.9E-09 272 -4.9E+00 1.6E+00 1.8E-03 301 2.8E-08 8.6E-01\ncg04776860 7 43177046 HECW1 2.3E-02 3.1E-02 4.6E-01 150 -6.8E-04 9.5E-05 1.2E-11 272 -1.3E+00 1.8E+00 4.8E-01 303 3.1E-08 2.6E-01\ncg17016145 6 141520754 4.5E-03 2.9E-02 8.8E-01 150 -6.2E-04 8.7E-05 9.3E-12 272 1.3E+00 1.9E+00 5.1E-01 295 1.1E-07 4.5E-01\ncg14696064 3 123010055 ADCY5 -7.9E-03 1.8E-02 6.7E-01 150 -5.3E-04 7.9E-05 7.5E-11 272 -1.4E+00 1.5E+00 3.4E-01 299 1.1E-07 8.4E-01\ncg06358636 6 133480830 -5.8E-03 1.1E-02 5.9E-01 150 -4.9E-04 7.3E-05 1.9E-10 272 3.1E+00 2.8E+00 2.7E-01 300 1.4E-07 9.7E-01\ncg12325049 3 9989666 PRRT3 -3.0E-02 2.2E-02 1.7E-01 150 -4.1E-04 7.2E-05 2.6E-08 272 -3.0E+00 1.4E+00 3.4E-02 283 2.0E-07 6.3E-01\ncg22798384 13 114889589 RASA3 -1.4E-02 1.5E-02 3.6E-01 150 -6.2E-04 9.2E-05 1.6E-10 272 6.7E-01 1.7E+00 6.9E-01 300 2.0E-07 3.7E-02\ncg27590143 7 51175394 COBL -4.1E-02 3.3E-02 2.2E-01 150 -9.0E-04 1.4E-04 7.5E-10 272 8.7E-01 1.9E+00 6.5E-01 297 3.2E-07 8.7E-01\ncg00334863 22 42779093 NFAM1 6.5E-03 1.9E-02 7.3E-01 150 -8.2E-04 1.4E-04 4.0E-09 272 -3.3E+00 1.8E+00 5.6E-02 295 4.5E-07 2.2E-01\ncg13808936 9 136371164 -1.4E-02 1.1E-02 2.0E-01 150 -6.8E-04 1.1E-04 3.2E-09 272 -1.1E+00 1.4E+00 4.6E-01 292 4.7E-07 2.5E-01\ncg11626582 10 3761802 -7.9E-03 1.5E-02 6.1E-01 150 -6.6E-04 1.0E-04 9.5E-10 272 1.4E+00 1.6E+00 3.7E-01 301 5.5E-07 3.8E-01\ncg13819687 9 35404785 UNC13B 1.7E-02 1.8E-02 3.5E-01 150 -8.9E-04 1.4E-04 6.0E-10 272 -4.8E-01 2.0E+00 8.1E-01 303 7.6E-07 1.6E-01\ncg10116904 1 190068092 FAM5C 1.2E-02 1.7E-02 4.9E-01 150 -5.7E-04 1.0E-04 3.6E-08 272 -4.4E+00 2.4E+00 7.1E-02 302 1.2E-06 8.4E-01\ncg15775406 7 1333612 2.2E-02 1.9E-02 2.5E-01 150 -5.4E-04 9.2E-05 1.1E-08 272 1.6E+00 2.0E+00 4.3E-01 297 1.2E-06 6.4E-01\ncg22201573 4 2278303 ZFYVE28 -5.7E-02 5.1E-02 2.6E-01 150 -1.1E-03 1.8E-04 1.9E-09 272 -1.9E-01 1.4E+00 8.9E-01 299 2.0E-06 8.6E-01\ncg02196671 14 104931470 5.6E-02 4.8E-02 2.5E-01 150 -3.7E-04 6.0E-05 2.3E-09 272 2.0E-01 1.7E+00 9.1E-01 303 2.4E-06 5.6E-01\ncg12635044 2 235406891 ARL4C -2.1E-02 2.6E-02 4.2E-01 150 -8.3E-04 1.5E-04 5.3E-08 272 2.3E+00 1.7E+00 1.7E-01 295 2.4E-06 4.5E-01\ncg08728732 10 105362705 SH3PXD2A -1.0E-02 9.9E-03 3.0E-01 150 -5.7E-04 1.0E-04 5.0E-08 272 2.4E+00 2.1E+00 2.7E-01 296 2.5E-06 6.5E-01\ncg25709679 15 99206764 IGF1R -8.2E-03 3.2E-02 8.0E-01 150 -8.5E-04 1.3E-04 3.4E-10 272 4.8E-01 2.7E+00 8.6E-01 285 2.6E-06 9.9E-01\ncg19140602 10 28233109 ARMC4 1.3E-02 3.5E-02 7.2E-01 150 -5.7E-04 9.2E-05 2.0E-09 272 -7.1E-01 1.5E+00 6.4E-01 303 2.7E-06 8.7E-01\nModel adjusted for sex and age. Meta-analysis in AA participants using p-values with logit method based on the general fixed effect model. The corresponding p-value for false positive rate (FDR) <0.05 was 2.7E-06 in meta-analysis in AA particiants. Bonferroni corrected p-value threshold in lookup in global meta-analysis in EA participants was 0.05/26 (0.002). MESA=Multi-Ethnic Study of Atherosclerosis study. CARDIA=Coronary Artery Risk Development in Young Adults study. GENOA=Genetic Epidemiology Network of Arteriopathy. EA=European ancestry. AA=African ancestry. CpG=DNA methylation site. CHR=chromosome. SE=standard error.\nSupplemental Table 8. 26 CpGs identified (FDR <0.05) in AA participants in the MESA, CARDIA, and GENOA cohorts. GENOA MESA CARDIA\nMeta-analysis P Global meta-analysis in EA population\nAnnotated gene CHR Full Name Gene type Description ABCG1 21 ATP binding cassette subfamily G member 1 protein coding The protein this gene encodes is involved in macrophage\ncholesterol and phospholipids transport; may regulate cellular lipid homeostasis\nASAM 11 CXADR like membrane protein protein coding Expression of this gene in white adipose tissue is implicated in adipocyte maturation and development of obesity.\nCPT1A 11 carnitine palmitoyltransferase 1A protein coding CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and the rate of fatty acid beta-oxidation.\nDHCR24 1 24-dehydrocholesterol reductase protein coding This gene encodes a flavin adenine dinucleotide-dependent oxidoreductase which is involved in cholesterol biosynthesis.\nGARS 7 glycyl-tRNA synthetase protein coding This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids.\nPHGDH 1 phosphoglycerate dehydrogenase protein coding This gene encodes the enzyme which is involved in the early steps of L-serine synthesis in animal cells and other amino acid synthesis.\nRPS6KA2 6 ribosomal protein S6 kinase A2 protein coding This gene encodes a member of the ribosomal S6 kinase family of serine/threonine kinases, which has been implicated in controlling cell growth and differentiation.\nSARS 1 seryl-tRNA synthetase protein coding This gene belongs to the class II amino-acyl tRNA family. The encoded enzyme catalyzes the transfer of L-serine to tRNA (Ser) and is related to bacterial and yeast counterparts.\nSC4MOL 4 methylsterol monooxygenase 1 protein coding Sterol-C4-mehtyl oxidase-like protein is localized to the endoplasmic reticulum membrane and is believed to function in cholesterol biosynthesis.\nSKI 1 SKI proto-oncogene protein coding This gene encodes the nuclear protooncogene protein homolog of avian sarcoma viral (v-ski) oncogene. It functions as a repressor of TGF-beta signaling, and may play a role in neural tube development and muscle differentiation\nSLC1A5 19 solute carrier family 1 member 5 protein coding The SLC1A5 gene encodes a sodium-dependent neutral amino acid transporter that can act as a receptor for RD114/type D retrovirus\nSLC43A1 11 solute carrier family 43 member 1 protein coding SLC43A1 belongs to the system L family of plasma membrane carrier proteins that transports large neutral amino acids\nSLC7A11 4 solute carrier family 7 member 11 protein coding This gene encodes a member of a heteromeric, sodiumindependent, anionic amino acid transport system that is highly specific for cysteine and glutamate.\nSLC9A3R1 17 SLC9A3 regulator 1 protein coding This gene encodes a sodium/hydrogen exchanger regulatory cofactor.\nSREBF1 17 sterol regulatory element binding transcription factor 1 protein coding This gene encodes a basic helix-loop-helix-leucine zipper transcription factor that binds to the sterol regulatory element1, which is a motif that is found in the promoter of the low density lipoprotein receptor gene and other genes involved in sterol biosynthesis.\nTBCD 17 tubulin folding cofactor D protein coding Cofactor D is one of four proteins involved in the pathway leading to correctly folded beta-tubulin from folding intermediates. Cofactor D is believed to play a role in capturing and stabilizing beta-tubulin intermediates in a quasinative confirmation.\nTXNIP 1 thioredoxin interacting protein protein coding This gene encodes a thioredoxin-binding protein that is a member of the alpha arrestin protein family. Thioredoxin is a thiol-oxidoreductase that functions as a regulator of cellular redox signaling, cellular metabolism, endoplasmic reticulum stress, and tumor suppression\nZFR2 19 zinc finger RNA binding protein 2 protein coding unknown\nSupplemental Table 9. Functional description for the 18 Illumina annotated genes.\nGene information is taken from NCBI Genes. CHR=chromosome."
    }, {
      "heading" : "Category Tissue Number of",
      "text" : "DEG\nNumber of input genes overlapping with DEG\nUpper tail p-value\nBonferroni corrected p-value\nGenes\nUp-regulated genes\nLiver 1920 6 1.02E-04 5.40E-03 DHCR24, SLC43A1, CPT1A, SREBF1, SLC9A3R1, SC4MOL\nDown-regulated genes\nLiver 5547 7 1.38E-02 7.29E-01 SARS, TBCD, SLC1A5, ABCG1, RPS6KA2, GARS, SKI\nSupplemental Table 10. Liver-specific differentially expressed genes in GTEx v6.\nGene set enrichment analysis depicts genes that are upregulated and downregulated in the liver by overlapping Illumina annotated genes with DEG. GTEx=Genotype-Tissue Expression. DEG=differentially expressed genes.\nGO biological process complete Ref List Observed Observed Genes Expected Representation Fold Enrichment P-value FDR positive regulation of cholesterol biosynthetic process (GO:0045542) 5 2 ABCG1, SREBF1 0 + > 100 1.61E-05 1.94E-02 positive regulation of sterol biosynthetic process (GO:0106120) 5 2 ABCG1, SREBF1 0 + > 100 1.61E-05 1.80E-02 positive regulation of cholesterol metabolic process (GO:0090205) 6 2 ABCG1, SREBF1 0.01 + > 100 2.15E-05 2.24E-02 amyloid precursor protein catabolic process (GO:0042987) 9 2 ABCG1, DHCR24 0.01 + > 100 4.22E-05 3.67E-02 L-alpha-amino acid transmembrane transport (GO:1902475) 41 3 SLC1A5, SLC43A1, SLC7A11 0.04 + 81.03 8.05E-06 1.26E-02 serine family amino acid metabolic process (GO:0009069) 42 3 SARS, GARS, PHGDH 0.04 + 79.11 8.62E-06 1.23E-02 L-amino acid transport (GO:0015807) 61 3 SLC1A5, SLC43A1, SLC7A11 0.06 + 54.47 2.50E-05 2.45E-02 amino acid transmembrane transport (GO:0003333) 72 3 SLC1A5, SLC43A1, SLC7A11 0.07 + 46.14 4.03E-05 3.71E-02 carboxylic acid transmembrane transport (GO:1905039) 112 4 CPT1A, SLC1A5, SLC43A1, SLC7A11 0.1 + 39.55 3.18E-06 2.48E-02 organic acid transmembrane transport (GO:1903825) 112 4 CPT1A, SLC1A5, SLC43A1, SLC7A11 0.1 + 39.55 3.18E-06 1.66E-02 cholesterol metabolic process (GO:0008203) 113 4 ABCG1, SREBF1, DHCR24, SC4MOL 0.1 + 39.2 3.29E-06 1.29E-02 secondary alcohol metabolic process (GO:1902652) 119 4 ABCG1, SREBF1, DHCR24, SC4MOL 0.11 + 37.23 4.01E-06 8.96E-03 sterol metabolic process (GO:0016125) 132 4 ABCG1, SREBF1, DHCR24, SC4MOL 0.12 + 33.56 5.98E-06 1.04E-02 organic acid transport (GO:0015849) 269 5 CPT1A, SLC9A3R1, SLC1A5, SLC43A1, SLC7A11 0.24 + 20.59 3.60E-06 1.13E-02 carboxylic acid transport (GO:0046942) 269 5 CPT1A, SLC9A3R1, SLC1A5, SLC43A1, SLC7A11 0.24 + 20.59 3.60E-06 9.38E-03 organic anion transport (GO:0015711) 414 6 ABCG1, CPT1A, SLC9A3R1, SLC1A5, SLC43A1, SLC7A11 0.37 + 16.05 1.32E-06 2.07E-02 anion transport (GO:0006820) 534 6 ABCG1, CPT1A, SLC9A3R1, SLC1A5, SLC43A1, SLC7A11 0.48 + 12.44 5.64E-06 1.10E-02 small molecule metabolic process (GO:0044281) 1836 8 ABCG1, SARS, SREBF1, SC4MOL, GARS, CPT1A, PHGDH, DHCR24 1.66 + 5.43 1.22E-05 1.59E-02\nSupplemental Table 11. The Enriched Biological Processes for Genes Mapped to the 18 Illumina annotated genes.\nRef List quanitifies the number of genes in the database for the GO analysis. The 'Observed' column quantifies the number of genes in the testing set. The 'Expected' column depicts the expected number of genes for the testing set. When comparing the observed versus expected number of genes, '+' denotes over-representation while '-' denotes under-representation. Raw p-values are reported along with the FDR threshold. GO=gene ontology. FDR=false discovery rate.\nCpG Independent cis - meQTL (1) P-value for independent cis - meQTL with CpG cis -meQTL overlapped with GWAS (2) P-value for cis - meQTL overlapped with GWAS with CpG LD R-squared b/w (1) and (2) CHR for cis - meQTL overlapped with GWAS BP for cis - meQTL overlapped with GWAS Trait\nP-value in GWAS PMID\ncg19016694 rs78483419 2.6E-12 rs9896933 NA 0.92 17 80870884 Bone mineral accretion in asthma (oral corticosteroid dose interaction) 3.0E-08 26025128 cg18120259 rs9472155 1.2E-82 rs9472155 1.2E-82 1 6 43897727 Vascular endothelial growth factor levels 2.0E-26 21757650 cg17501210 rs239934 7.1E-24 rs2236313 3.7E-14 0.68 6 167360389 Vitiligo 1.0E-16 20526339 cg17501210 rs239934 7.1E-24 rs2149085 6.4E-23 0.98 6 167371110 Crohn's disease 8.0E-12 23850713 cg17501210 rs239934 7.1E-24 rs1819333 5.9E-23 0.98 6 167373547 Inflammatory bowel disease 7.0E-21 23128233 cg17501210 rs239934 7.1E-24 rs1819333 5.9E-23 0.98 6 167373547 Crohn's disease 2.0E-19 26192919 cg17501210 rs239934 7.1E-24 rs1819333 5.9E-23 0.98 6 167373547 Inflammatory bowel disease 1.0E-06 27569725 cg17501210 rs239934 7.1E-24 rs1819333 5.9E-23 0.98 6 167373547 Crohn's disease 2.0E-20 28067908 cg17501210 rs239934 7.1E-24 rs1819333 5.9E-23 0.98 6 167373547 Inflammatory bowel disease 9.0E-15 28067908 cg17501210 rs2345568 1.8E-16 rs9355610 2.0E-16 0.97 6 167383075 Graves' disease 7.0E-10 21841780 cg17501210 rs239934 7.1E-24 rs444210 2.4E-21 0.92 6 167390242 Inflammatory bowel disease 2.0E-17 26192919 cg17501210 rs239934 7.1E-24 rs9457247 1.8E-23 0.98 6 167392174 Crohn's disease 2.0E-18 26192919 cg17501210 rs2345568 1.8E-16 rs4710154 7.8E-16 0.98 6 167394634 Basal cell carcinoma 1.0E-08 27539887 cg17501210 rs239934 7.1E-24 rs415890 2.3E-23 0.98 6 167406633 Crohn's disease 3.0E-12 21102463 cg17501210 rs2038580 1.8E-16 rs2301436 1.6E-17 0.76 6 167437988 Crohn's disease 1.0E-12 18587394 cg17501210 rs2038580 1.8E-16 rs2301436 1.6E-17 0.76 6 167437988 Crohn's disease 6.0E-08 20570966 cg17501210 rs2038580 1.8E-16 rs6456156 1.4E-06 0.6 6 167522300 Primary biliary cholangitis 6.0E-07 28425483 cg17501210 rs2038580 1.8E-16 rs3093024 2.7E-07 0.71 6 167532793 Rheumatoid arthritis 8.0E-19 20453841 cg17501210 rs2038580 1.8E-16 rs1854853 1.9E-06 0.65 6 167533062 Rheumatoid arthritis 2.0E-10 24782177 cg17501210 rs2038580 1.8E-16 rs3093023 1.2E-07 0.73 6 167534290 Rheumatoid arthritis 2.0E-11 20453842 cg17501210 rs2038580 1.8E-16 rs3093023 1.2E-07 0.73 6 167534290 Rheumatoid arthritis 4.0E-09 24782177 cg17501210 rs2038580 1.8E-16 rs1571878 3.5E-07 0.71 6 167540842 Rheumatoid arthritis 5.0E-35 24390342 cg14476101 rs866321 1.3E-37 rs1163251 4.3E-36 0.98 1 120209755 Blood metabolite levels 7.0E-27 24816252 cg14476101 rs666930 3.3E-09 rs637868 3.6E-09 0.97 1 120257110 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) 4.0E-07 28090653 cg14476101 rs11583993 2.7E-127 rs894079 4.7E-64 0.66 1 120263657 Severe gingival inflammation 1.0E-06 28459102 cg14476101 rs41276626 3.5E-15 rs12144094 4.9E-15 0.98 1 120264823 Height 2.0E-09 25282103 cg11376147 rs2511992 9.7E-06 rs2729354 NA 0.98 11 57358343 Blood protein levels 8.0E-14 28240269 cg11024682 rs7214988 6.5E-16 rs11658311 3.1E-14 0.97 17 17470526 Obsessive-compulsive symptoms 7.0E-06 26859814 cg11024682 rs12936587 1.8E-10 rs12936587 1.8E-10 1 17 17543722 Coronary heart disease 4.0E-10 21378990 cg11024682 rs12936587 1.8E-10 rs12936587 1.8E-10 1 17 17543722 Coronary artery disease or large artery stroke 2.0E-10 24262325 cg11024682 rs12936587 1.8E-10 rs12936587 1.8E-10 1 17 17543722 Hip circumference 3.0E-08 25673412 cg11024682 rs12936587 1.8E-10 rs12449964 2.2E-10 0.98 17 17544704 Coronary artery disease or ischemic stroke 2.0E-08 24262325 cg11024682 rs941444 1.1E-20 rs12941356 9.4E-19 0.71 17 17716531 Resting heart rate 5.0E-08 27798624 cg11024682 rs1889014 2.6E-22 rs8082590 1.1E-05 0.67 17 17958402 Schizophrenia 2.0E-08 25056061 cg11024682 rs1889014 2.6E-22 rs8082590 1.1E-05 0.67 17 17958402 Schizophrenia 2.0E-08 26198764 cg08309687 rs4817600 6.1E-09 rs2834288 2.3E-05 0.62 21 35264397 Gut microbiota (bacterial taxa) 2.0E-08 27694959 cg08309687 rs2032314 6.4E-17 rs2032314 6.4E-17 1 21 35354523 Red blood cell traits 8.0E-10 23222517 cg02711608 rs7247877 2.7E-13 rs314669 4.8E-10 0.72 19 47168129 Glaucoma (primary open-angle) 2.0E-06 27001270 cg02711608 rs11668911 1.2E-21 rs11083846 1.0E-17 0.8 19 47207654 Chronic lymphocytic leukemia 4.0E-09 18758461 cg27243685 rs57137919 2.9E-09 rs4148087 8.0E-09 0.86 21 43622267 Eating disorder in bipolar disorder 4.0E-07 26433762 cis -meQTL=cis -methylation quantitative trait loci. CpG=DNA methylation site. CHR=chromosome. BP=base pair. GWAS=genome-wide association study. PMID=PubMed identification number\nSupplemental Table 12. Traits associated with cis -meQTLs or proxies of cis -meQTLs using the NHGRI-EBI GWAS Catalog.\nCpG Gene CHR CpG position TSS P-value for CpG and gene association P-value for gene and liver fat association\nDirection for CpG and liver fat association Direction for CpG and gene association Direction for gene and liver fat association\ncg06500161 ABCG1 21 43656587 43619809 2.1E-60 1.2E-30 + - - cg27243685 ABCG1 21 43642366 43619809 1.2E-37 1.2E-30 + - - cg00574958 CPT1A 11 68607622 68522090 1.9E-20 2.0E-17 - - + cg17901584 DHCR24 1 55353706 55302242 6.3E-17 1.2E-01 - - + cg06690548 SLC7A11 4 139162808 139060406 6.1E-14 3.7E-01 - - + cg14476101 PHGDH 1 120255992 120202441 3.7E-12 3.2E-02 - - + cg17501210 RNASET2 6 166970252 167271494 9.4E-11 7.7E-02 - - - cg19693031 TXNIP 1 145441552 145438489 8.2E-08 7.8E-03 - - - cg08309687 ATP5O 21 35320596 35273997 2.2E-04 8.7E-01 - + + cg08309687 TMEM50B 21 35320596 34804794 6.3E-04 4.1E-05 - + - cg08309687 ITSN1 21 35320596 35014716 6.5E-03 2.3E-02 - + + cg08309687 SLC5A3 21 35320596 35467498 1.4E-02 2.0E-01 - - - cg08309687 MRPS6 21 35320596 35322421 4.5E-02 5.5E-01 - - +\nSupplemental Table 13. Three-way association of CpGs, gene expression, and hepatic fat in the FHS.\nGene expression levels were derived from whole blood in the FHS. Regarding direction, '+' sign represents a positive association and '-' sign represents an inverse association. CpG=DNA methylation site. FHS=Framingham Heart Study. CHR=chromosome. TSS=transcription start site.\nBeta SE P Beta SE P Beta SE P number of IVs IVs Mean Min Max CpG T2D Q statistics P-for-Q statistics\ncg02711608 -0.73 3.05 0.81 4 rs1060043, rs1862335, rs3027961, rs8102896 31 11 52 0.08 3.5E-04 2.50 0.47\ncg06500161 -0.38 3.88 0.92 2 rs225443, rs9978671 29 17 42 0.03 1.1E-04 0.81 0.37\ncg08309687 -4.99 1.36 2.5E-04 -3.97 2.57 0.17 -0.01 0.01 0.66 9 rs11702633, rs17655956, rs2070393, rs2244966, rs2834311, rs2834321, rs743316, rs9636874, rs9978794\n55 10 162 0.15 2.7E-03 6.04 0.64\ncg09469355 1.01 10.76 0.92 3 rs12049067, rs3107125, rs4648832 20 10 33 0.01 6.8E-04 4.60 0.10\ncg11024682 2.45 2.76 0.37 4 rs1006656, rs11656629, rs11658477, rs1889014 73 17 139 0.09 2.3E-04 0.89 0.83\ncg14020176 -1.39 5.82 0.81 2 rs895690, rs939543 31 16 47 0.03 1.4E-05 0.04 0.83\ncg14476101 -2.44 1.00 0.01 -0.08 1.80 0.97 -0.02 0.01 0.15 11 rs10802118, rs1177389, rs1886736, rs372814, rs3862258, rs4659015, rs4844381, rs6667104, rs667226, rs7528420, rs866321 85 10 382 0.22 1.7E-03 6.71 0.75\ncg15860624 6.69 5.49 0.22 3 rs10410543, rs12459781, rs2060249 25 21 29 0.02 8.3E-04 2.12 0.35\ncg17501210 2.95 4.95 0.55 2 rs239935, rs9356478 50 30 70 0.04 4.3E-04 2.29 0.13\ncg17901584 -1.14 4.66 0.81 1 rs3170766 38 38 38 0.02 8.3E-06\ncg18120259 -2.31 2.38 0.33 4 rs866730, rs9472153, rs9472155, rs9472159 50 12 151 0.12 1.8E-03 10.47 0.01\ncg19016694 3.93 2.45 0.11 5 rs12943585, rs3791160, rs4789817, rs4986117, rs6416854 49 14 163 0.10 7.4E-04 2.67 0.62\ncg21429551 -3.94 3.00 0.19 1 rs6462211 34 34 34 0.01 2.4E-04\ncg27243685 -5.22 6.39 0.41 2 rs221954, rs748319 34 30 38 0.02 2.3E-04 0.96 0.33"
    }, {
      "heading" : "A positive beta value means that the instrument SNPs (cis-meQTLs) increased DNA methylation and increased hepatic fat, whereas a negative beta value means that the instrument SNPs increased DNA methylation but reduced hepatic fat. The inverse variance weighted (IVW) approach was implemented for all CpGs and the MR-Egger method was implemented for CpGs with three or more instrumental variables (IVs) and significant using",
      "text" : "IVW. MR=Mendelian randomization. CpG=DNA methylation site. SNP=single nucleotide polymorphism. SE=standard error.\nCpG\nSupplemental Table 14. MR analysis for CpGs association to nonalcoholic fatty liver disease (NAFLD)\nExplained variance by SNPs HeterogeneityIVW method Egger method\nEgger method intercept (horizontal\npleiotropy) F-statistics of Ivs\nCpG OR 95% CI P OR 95% CI P cg09469355 0.78 0.78 (0.67, 0.9) 1.2E-03 0.85 0.85 (0.73, 1) 4.7E-02 cg17901584 0.44 0.44 (0.37, 0.53) 1.9E-18 0.53 0.53 (0.43, 0.63) 2.9E-11 cg03725309 0.51 0.51 (0.42, 0.62) 8.7E-12 0.62 0.62 (0.5, 0.76) 8.1E-06 cg14476101 0.70 0.7 (0.62, 0.79) 3.3E-08 0.79 0.79 (0.69, 0.91) 8.8E-04 cg19693031 0.47 0.47 (0.41, 0.53) 5.6E-30 0.48 0.48 (0.42, 0.55) 1.5E-26 cg06690548 0.82 0.82 (0.74, 0.91) 2.5E-04 0.91 0.91 (0.81, 1.03) 1.3E-01 cg05119988 0.65 0.65 (0.57, 0.74) 1.0E-11 0.68 0.68 (0.6, 0.77) 5.1E-09 cg03957124 0.66 0.66 (0.53, 0.83) 2.7E-04 0.83 0.83 (0.66, 1.05) 1.2E-01 cg18120259 0.77 0.77 (0.64, 0.93) 7.7E-03 0.91 0.91 (0.74, 1.11) 3.5E-01 cg17501210 0.74 0.74 (0.65, 0.85) 9.2E-06 0.87 0.87 (0.76, 1) 5.1E-02 cg21429551 0.71 0.71 (0.62, 0.8) 9.8E-08 0.79 0.79 (0.69, 0.9) 5.6E-04 cg11376147 0.59 0.59 (0.48, 0.72) 4.1E-07 0.67 0.67 (0.54, 0.82) 1.6E-04 cg00574958 0.44 0.44 (0.38, 0.52) 1.2E-22 0.54 0.54 (0.46, 0.64) 9.2E-13 cg26894079 0.91 0.91 (0.77, 1.07) 2.5E-01 1.01 1.01 (0.86, 1.18) 9.1E-01 cg11024682 1.49 1.49 (1.32, 1.69) 1.9E-10 1.33 1.33 (1.17, 1.5) 6.6E-06 cg14020176 1.50 1.5 (1.28, 1.75) 4.6E-07 1.40 1.4 (1.19, 1.64) 5.8E-05 cg19016694 0.86 0.86 (0.72, 1.03) 1.0E-01 1.02 1.02 (0.85, 1.21) 8.5E-01 cg15860624 1.18 1.18 (1.03, 1.35) 1.9E-02 1.09 1.09 (0.95, 1.25) 2.2E-01 cg02711608 0.57 0.57 (0.47, 0.68) 7.3E-10 0.66 0.66 (0.55, 0.79) 8.5E-06 cg08309687 0.73 0.73 (0.63, 0.84) 1.8E-05 0.81 0.81 (0.7, 0.94) 4.7E-03 cg27243685 1.50 1.5 (1.31, 1.72) 1.0E-08 1.34 1.34 (1.16, 1.54) 5.0E-05 cg06500161 1.90 1.9 (1.67, 2.17) 1.6E-21 1.66 1.66 (1.45, 1.91) 4.7E-13\nModel 2 adjusted for model 1 covariates and BMI.\nSupplemental Table 15. Cross-sectional association between hepatic fat-associated CpGs with prevalence of type 2 diabetes in 4,068 Framingham Heart Study participants\nModel 1 Model 2\nModel 1 adjusted for sex, age, alcohol intake, smoking status, physical activity level, laboratory for DNA methylation assessment, DNA methylation chip ID, row, and column, top three PCs, and estimated leukocyte composition."
    }, {
      "heading" : "CpGs",
      "text" : "Beta SE P Beta SE P Beta SE P number of IVs Ivs Mean Min Max CpG T2D Q statistics P-for-Q statistics\ncg02711608 -0.27 1.06 0.80 6 rs11668911, rs151217961, rs1862335, rs3027960, rs7260181, rs8102896\n26 11 52 0.09 1.7E-05 3.91 0.56\ncg06500161 1.84 1.41 0.19 2 rs225443, rs9982016 29 17 41 0.03 7.3E-06 0.01 0.91 cg08309687 -0.47 0.53 0.37 16 rs10222139, rs117631025, rs190361590, rs2243871,\nrs2834259, rs2834311, rs2834321, rs35070015, rs7277233, rs73199882, rs78070167, rs78449000, rs78713112, rs879489, rs9636874, rs9978794\n38 13 162 0.20 9.5E-05 21.03 0.10\ncg09469355 -2.41 2.14 0.26 3 rs3107125, rs56117848, rs870207 22 11 37 0.02 8.6E-06 0.60 0.74 cg11024682 1.10 2.54 0.67 5 rs11655294, rs11656699, rs1889014, rs35367147,\nrs9916193 80 18 156 0.13 1.5E-04 33.17 1.1E-06\ncg14020176 -9.75 1.95 5.6E-07 2 rs62084914, rs939543 33 16 50 0.03 1.0E-04 0.003 0.96 cg14476101 0.02 0.29 0.95 17 rs10802118, rs11583993, rs1163550, rs12065721,\nrs12121447, rs148882526, rs190242852, rs347911, rs4659015, rs4844381, rs517533, rs518027, rs6667104, rs667226, rs67607949, rs79140708, rs911245\n87 10 603 0.36 8.2E-05 19.06 0.27\ncg15860624 -4.68 1.58 0.003 0.25 6.27 0.97 -0.02 0.02 0.56 3 rs10410543, rs12459781, rs8111014 24 21 29 0.02 4.3E-05 1.74 0.42 cg17501210 0.58 1.07 0.59 3 rs239934, rs57794755, rs7757549 39 15 72 0.05 6.7E-06 1.27 0.53 cg17901584 -0.67 1.60 0.68 1 rs12732413 35 35 35 0.02 7.4E-07 cg18120259 -1.49 0.68 0.03 -0.34 1.28 0.81 -0.01 0.01 0.40 4 rs2759270, rs67798973, rs9472155, rs9472159 53 14 151 0.13 3.5E-05 3.29 0.35 cg19016694 0.22 0.78 0.78 8 rs12601746, rs4986127, rs4986139, rs756072,\nrs78056681, rs78483419, rs8064531, rs8076137 37 12 164 0.13 1.9E-05 4.27 0.75\ncg21429551 -2.37 1.09 0.03 1 rs6462211 34 34 34 0.01 2.0E-05 cg27243685 0.15 2.02 0.94 2 rs748319, rs77704026 35 32 38 0.03 2.7E-06 0.62 0.43\nSupplemental Table 16. MR analysis for causal associations from CpGs to type 2 diabetes\nF-statistics of Ivs Explained variance by SNPs Heterogeneity\nThe inverse variance weighted (IVW) approach was implemented for all CpGs and the MR-Egger method was implemented for CpGs with three or more instrumental variables (IVs) and significant using IVW. MR=Mendelian randomization. FHS=Framingham Heart Study. CpG=DNA methylation site. SNP=single nucleotide polymorphism. SE=standard error.\nIVW method Egger method Egger method intercept (horizontal pleiotropy)"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 0,
    "abstractText" : null,
    "creator" : null
  }
}